Every one of those 1 sits in a single category, fda-approval. Illinois is most often covered alongside Dilation and Curettage (D&C), which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Illinois, all published on July 21, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Illinois
Every one of those 1 sits in a single category, fda-approval. Illinois is most often covered alongside Dilation and Curettage (D&C), which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Illinois, all published on July 21, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Illinois. Shared-story counts are live from our verified record — not editorial picks.
Regulatory chaos after Dobbs is freezing innovation in miscarriage management drugs and devices, delaying emergency care and leaving a $2.3 billion women’s health market in limbo. Vague exceptions in 13 state bans create a minefield for pharma companies developing early pregnancy loss treatments.